Locations:
Search
Options expand for patients with cancer and other conditions
Patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
Timing and type of side effects differ greatly from chemotherapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic researchers pursue answers on basic science and clinical fronts
Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients
Two thirds of patients responded to CAR T-cell therapy
Belzutifan superior to everolimus in phase 3 clinical trial
Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial
Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia
Advertisement
Advertisement